• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.

作者信息

Bachurin S O, Ustyugov A A, Peters O, Shelkovnikova T A, Buchman V L, Ninkina N N

机构信息

Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia.

出版信息

Dokl Biochem Biophys. 2009 Sep-Oct;428:235-8. doi: 10.1134/s1607672909050032.

DOI:10.1134/s1607672909050032
PMID:20848907
Abstract
摘要

相似文献

1
Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.
Dokl Biochem Biophys. 2009 Sep-Oct;428:235-8. doi: 10.1134/s1607672909050032.
2
Morphinan neuroprotection: new insight into the therapy of neurodegeneration.吗啡喃神经保护作用：神经退行性疾病治疗的新见解。
Crit Rev Neurobiol. 2004;16(4):271-302. doi: 10.1615/critrevneurobiol.v16.i4.30.
3
P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition.P7C3-A20 治疗创伤性脑损伤一年后的小鼠修复血脑屏障，阻止慢性神经退行性变，并恢复认知功能。
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27667-27675. doi: 10.1073/pnas.2010430117. Epub 2020 Oct 21.
4
New Therapeutic Property of Dimebon as a Neuroprotective Agent.地美溴铵作为神经保护剂的新治疗特性。
Curr Med Chem. 2018;25(39):5315-5326. doi: 10.2174/0929867323666160804122746.
5
Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?具有神经保护活性的β-突触核蛋白衍生肽：神经退行性疾病的一种替代治疗方法？
J Mol Neurosci. 2004;24(1):155-65. doi: 10.1385/JMN:24:1:155.
6
Regulation of neuroinflammation by herbal medicine and its implications for neurodegenerative diseases. A focus on traditional medicines and flavonoids.草药对神经炎症的调节及其对神经退行性疾病的影响。聚焦传统药物和黄酮类化合物。
Neurosignals. 2005;14(1-2):23-33. doi: 10.1159/000085383.
7
3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions.3-取代吲哚酮作为治疗神经退行性疾病的新型治疗化合物。
Exp Biol Med (Maywood). 2008 Nov;233(11):vi.
8
Farnesol quells oxidative stress, reactive gliosis and inflammation during acrylamide-induced neurotoxicity: Behavioral and biochemical evidence.法尼醇可减轻丙烯酰胺诱导的神经毒性过程中的氧化应激、反应性胶质增生和炎症：行为学和生物化学证据。
Neuroscience. 2015 Nov 12;308:212-27. doi: 10.1016/j.neuroscience.2015.08.067. Epub 2015 Sep 1.
9
Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.调节淀粉样蛋白的自组装作为神经退行性疾病的治疗方法：策略和机制。
ChemMedChem. 2012 Mar 5;7(3):359-74. doi: 10.1002/cmdc.201100585. Epub 2012 Feb 9.
10
Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.一种新型α7烟碱型乙酰胆碱受体激动剂治疗神经退行性疾病和认知障碍的促认知及神经保护活性
J Pharmacol Exp Ther. 2009 May;329(2):459-68. doi: 10.1124/jpet.108.150094. Epub 2009 Feb 17.

引用本文的文献

1
Gamma-Carbolines Derivatives As Promising Agents for the Development of Pathogenic Therapy for Proteinopathy.γ-咔啉衍生物有望成为蛋白质病致病疗法开发的药物。
Acta Naturae. 2018 Oct-Dec;10(4):59-62.
2
Gamma-carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis.γ-咔啉在肌萎缩侧索硬化症转基因模型中抑制神经退行性变过程。
Dokl Biochem Biophys. 2015;462:189-92. doi: 10.1134/S1607672915030138. Epub 2015 Jul 12.
3
Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).地美波恩（拉替普啶）的新型神经保护作用部位。

本文引用的文献

1
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.二甲金刚胺对轻至中度阿尔茨海默病患者认知、日常生活活动能力、行为及整体功能的影响：一项随机、双盲、安慰剂对照研究
Lancet. 2008 Jul 19;372(9634):207-15. doi: 10.1016/S0140-6736(08)61074-0.
2
A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.一条将α-突触核蛋白与载脂蛋白E及β淀粉样肽联系起来的神经退行性变分子通路。
Nat Neurosci. 2008 Mar;11(3):301-8. doi: 10.1038/nn2058. Epub 2008 Feb 24.
3
Cell systems and the toxic mechanism(s) of alpha-synuclein.
Mol Neurobiol. 2015 Oct;52(2):970-8. doi: 10.1007/s12035-015-9249-4. Epub 2015 Jun 30.
4
Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.拉替拉嗪：在阿尔茨海默病和其他神经退行性疾病的潜在治疗作用中的分子机制。
Transl Psychiatry. 2013 Dec 3;3(12):e332. doi: 10.1038/tp.2013.97.
5
Dimebon activates autophagosome components in human neuroblastoma SH-SY5Y cells.地美环素激活人神经母细胞瘤SH-SY5Y细胞中的自噬体成分。
Dokl Biochem Biophys. 2012 Sep-Oct;446:251-3. doi: 10.1134/S1607672912050079. Epub 2012 Nov 7.
6
Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.拉替拉嗪（二甲苯并嗪）可增强自噬作用，并降低酵母细胞内 GFP-Aβ42 的水平。
J Alzheimers Dis. 2012;32(4):949-67. doi: 10.3233/JAD-2012-120178.
7
FUS gene mutations associated with familiar forms of amyotrophic lateral sclerosis affect cellular localization and aggregation properties of the encoded protein.
Dokl Biochem Biophys. 2011 May-Jun;438:123-6. doi: 10.1134/S1607672911030045. Epub 2011 Jul 3.
8
Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.地美溴铵不能改善转染人源α-突触核蛋白（1-120）截断突变基因的多巴胺能神经元所致的病理改变。
Neurodegener Dis. 2011;8(6):430-7. doi: 10.1159/000324989. Epub 2011 May 12.
9
Testing the amyloid hypothesis of Alzheimer's disease in vivo.在体内测试阿尔茨海默病的淀粉样蛋白假说。
Lancet Neurol. 2010 Apr;9(4):333-5. doi: 10.1016/S1474-4422(10)70055-7. Epub 2010 Feb 26.
细胞系统与α-突触核蛋白的毒性机制
Exp Neurol. 2008 Jan;209(1):5-11. doi: 10.1016/j.expneurol.2007.05.022. Epub 2007 Jun 4.
4
Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies.阿尔茨海默病：抗淀粉样蛋白疾病修饰疗法的研发进展
CNS Spectr. 2007 Feb;12(2):113-6, 119-23. doi: 10.1017/s1092852900020629.
5
Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.针对阿尔茨海默病认知衰退和疾病修饰的治疗策略的当前概念
NeuroRx. 2005 Oct;2(4):612-26. doi: 10.1602/neurorx.2.4.612.
6
Emerging prospects for the disease-modifying treatment of Alzheimer's disease.阿尔茨海默病疾病修饰治疗的新前景。
Biochem Pharmacol. 2005 Apr 1;69(7):1001-8. doi: 10.1016/j.bcp.2004.12.015.
7
Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.γ-突触核蛋白、α-突触核蛋白及α/γ-突触核蛋白双敲除突变小鼠黑质致密部多巴胺能神经元的发育性缺失及对MPTP毒性的抗性
J Neurochem. 2004 Jun;89(5):1126-36. doi: 10.1111/j.1471-4159.2004.02378.x.
8
Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene.表达最高水平γ-突触核蛋白的神经元不受该基因靶向失活的影响。
Mol Cell Biol. 2003 Nov;23(22):8233-45. doi: 10.1128/MCB.23.22.8233-8245.2003.
9
Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer.抗组胺药地美环素作为一种新型神经保护剂和认知增强剂。
Ann N Y Acad Sci. 2001 Jun;939:425-35. doi: 10.1111/j.1749-6632.2001.tb03654.x.
10
[Action of dimebon on histamine receptors].[二苯美伦对组胺受体的作用]
Farmakol Toksikol. 1983 Jul-Aug;46(4):27-9.